target the immune system either systemically or locally (mesalamine, corticosteroids, azathioprine, etc) are used to treat both conditions. UC and CD, however, are distinct disease entities (2) . Inflammation in UC is confined to the mucosa, is limited to the colon and appears distally in the rectum, extending more proximally in a confluent pattern. CD, on the other hand, may affect any part of the gastrointestinal tract in a patchy distribution, although it commonly affects the small bowel (usually distal ileum) and colon. Unlike inflammation in UC, inflammation in CD can be transmural, resulting in intestinal fibrosis, lumenal stenosis and fistula formation between adjacent hollow organs (including skin) and other loops of intestine. Moreover, in UC, definitive surgical resection is curative whereas in CD, inflammatory recurrence is common. Both diseases often present with systemic symptoms (fever, fatigue, weight loss, etc) and both can have extra-intestinal manifestations (eg, cutaneous ulcers, arthritis and ocular inflammation) (3) .
Given the heterogeneous clinical features present in any cohort of CD patients, as well as the many possible surrogate laboratory markers of disease activity, it became necessary to develop an instrument that would accurately reflect the activity of CD. This instrument would have to incorporate the clinical features of the disease and any of its known laboratory markers. The instrument would have to demonstrate reliability and possess validity (both content and criterion), as well as demonstrate responsiveness to change in disease activity, in order to be suitable for use in clinical trials. Moreover, for such an instrument (and the clinical trials that employed such an instrument) to be accepted by experienced clinicians, it would have to possess face validity, ie, appear to reflect a bedside global assessment of CD activity.
In 1970, the National Cooperative Crohn's Disease Study (NCCDS) was initiated to test the efficacy and safety of prednisone, sulfasalazine and azathioprine in controlled clinical trials (4) . For this study, the investigators developed an instrument to assess CD severity and response to therapy. This instrument, the Crohn's Disease Activity Index (CDAI) (5) , was first used in clinical trials in 1972 and was the instrument of evaluation in two large trials that resulted from the NCCDS (6, 7) . Today, the CDAI remains widely used in clinical research. A random overview of important published clinical trials of the past four years (8) (9) (10) (11) (12) (13) reveals that more than 25 years after the CDAI was developed, it remains a popular instrument of evaluation of CD.
This article reviews the CDAI, and its development, reliability and validity. Other instruments developed subsequent to the CDAI, including quality of life indexes, are also reviewed.
DEVELOPMENT OF THE CDAI
The CDAI is a disease-specific index, ie, its use is restricted to CD and it is not applicable to IBD in general. The CDAI attempts to evaluate the activity of CD in several domains, each of which evaluates a specific aspect of CD. The CDAI sums up the weighted value of each item of the domain and quantifies the global disease severity in a final numerical score (5) .
The CDAI was not the first instrument that attempted to provide a global numerical score of disease severity using this approach. An earlier instrument, adapted from a medical doctoral thesis, was developed at St Bartholomew's Hospital (14) . In this earlier instrument, physicians assigned a grade of 0 to 3 to 11 features of CD ranging from lassitude, nausea and pain to ocular inflammation and fistulas. The unweighted sum of the index provided a global rating score of disease activity. Any reliability assessment of this instrument before its use in a clinical trial is unpublished. Likewise, the only validity assessment that can be ascertained from the brief description of the instrument is the reader's own face validity. The development of the CDAI by the investigators of the NCCDS, in contrast to that of the St Bartholomew's Index, was well documented (5).
In the development of any new health questionnaire or scale, there must be some method of selecting the instrument's items. Two techniques that have been described in devising items in the health sciences are the use of focus groups and clinical observation. Focus groups comprise small groups of 'informants' who have insight into the condition that is to be assessed (usually those affected by the condition) (15) . They generate general themes from which items can be derived.
Items derived from clinical observation are based on the opinions of experienced clinicians obtained at 'key informant interviews' (15) . Items in the CDAI were devised by combining both methods. Gastroenterologists with expertise in CD from 13 participating university centres (analogous to the focus group of health sciences research) drew upon their clinical experience and agreed upon a list of 18 parameters (Table 1) to be used (4, 5) . As can be seen in Table 1, the original list of items from the physician focus group sampled several different domains of CD, including subjective patient symptoms and need for symptomatic medications (eg, well-being, abdominal pain that wakes patient up, taking diphenoxylate hydrochloride, etc); objective clinical findings on physical examination (abdominal mass and tenderness, arthritis, etc); extra-intestinal manifestations of CD (eg, iritis and erythema nodosum); complications of CD (eg, fistulas); radiologic and endoscopic examinations (site of disease, distal ileal involvement, colitis, etc); and laboratory parameters (eg, serum albumin and hematocrit).
After the list of items and rating scales were devised, 112 patients with known CD were then studied prospectively. At each visit, patients were assessed by a gastroenterologist, and one-week diaries were completed. These 112 patients made a total of 186 visits. At each patient visit, the gastroenterologist recorded a global assessment score of their impression of the patient's disease activity (rating: "very well" = 1, "fair to good" = 3, "poor" = 5, "very poor" = 7). In the analysis of the CDAI variables, the principles of multiple regression analysis were applied to determine which of the 18 items correlated with the physicians' global assessment.
In a multiple regression model, the dependent variable (y) is related to the independent variables (x) in such a way that the relationship fits the general equation:
where b 0 is a constant (the y intercept) and b (1-n) are constant coefficients (slope of the line) of the independent variables (the x's). In determining the regression equation for a data set, the method of least squares (16) is employed. This least squares method determines the line of best fit between the observed value y (the points scattered around the line) and the y value predicted by equation (the line). In developing the CDAI, the physicians' global assessments of each of the 112 patients became the dependent variable (y) and the items selected by the focus group of gastroenterologists became the independent variables (x [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ). In this analysis, the y intercept (b 0 ) was set to zero. In deciding which items contributed to the multiple regression model, a method known as backwards step-wise was chosen. This method begins with the full nested model (ie, the initial model including all 18 independent variables). Each independent variable is then dropped from the equation and the remaining equation analyzed to determine whether the deletion of this variable had a significant effect on the remaining model (ie, the variable's effect on the model was more than that of chance as determined by an alpha level of significance such as P<0.05) (16) . This stepwise deletion is continued until only independent variables with significant coefficients remain in the model.
Using this method, the number of items of the CDAI were reduced from 18 to eight (Table 2) . Body weight was removed from the CDAI in the early computational analysis, however, because of its intuitive importance; it was reinserted only to have gained strength in subsequent stepwise analysis (5).
THE CDAI: THE FINAL INSTRUMENT
AND ITS APPLICATION One of the a priori requirements of the CDAI stipulated by the NCCDS was that the instrument be relatively simple to use. In order to convert a complicated multiple independent variable regression equation into an index that clinical investigators could use, each of the final coefficients (b (1) (2) (3) (4) (5) (6) (7) (8) ) of the equation was divided by the smallest coefficient, which was item 8 (body weight) (5) . Each of the adjusted coefficients was then rounded to the nearest integer. From this mathematical manipulation, a weighting scale ranging from 1 to 30 was produced (Table 2) . The actual mechanics of applying the CDAI to a study subject requires that the patient complete a three-item patient diary recording the number of stools per day over a one-week period, the degree of abdominal pain over a week (on a scale of 0 to 3 -"mild" to "severe") and daily general well-being (on a scale of 0 to 3 -"generally well" to "terrible"). Similarly, at each patient visit, the clinical findings on physician history and physical examination, as well as the relevant laboratory values, were recorded. The individual item scores were then multiplied by the item's weighting factor and the final score totalled (5) . In determining threshold cut-off values of the CDAI that indicated quiescent disease from active, the CDAI scores for the cohort of study patients were compared with the physician's global categorical assessment (ie, "very well" to "very poor") (5). A value less than 150 was defined as quiescent CD (ie, nonactive disease, clinical remission) whereas values greater than 450 were associated with extremely severe disease (5).
RELIABILITY OF THE CDAI
The reliability of a test or instrument in a general sense can be considered to represent the degree of consistency of the instrument's measurement. Reliability can be further defined as the proportion of subject variability to total variability (which includes both subject variability and, importantly, the variability introduced by the instrument's inherent error of measurement) (17) . The kappa statisticwhich is well-known to clinicians as a measure of interobserver agreement in diagnostic test interpretation beyond mere chance (eg, comparing chest radiograph interpretations between two radiologists) (18, 19) -is a form of reliability testing. Statistical tests of a health care instrument's reliability are the intraclass correlation coefficient (ICC) and the Pearson correlation coefficient (product moment correlation).
Best et al's (5) original report of the CDAI did not include formal tests of reliability. The original report did, however, examine the consistency of the instrument over two successive visits (ie, test-retest reliability) in 32 patients. The investigators noted a positive association between changes in the physician global assessment and the CDAI between visits with some overlap. The differential between patients considered slightly improved/worse versus the same was 50 index points. The investigators attempted to describe the within patient variation under relatively stable conditions using the pooled standard deviation of replication (ie, between assessments of patients unchanged between two visits), which was reported to be 45.1 CDAI units (5) . The co-efficient of correlation (which explains the degree of variability between the observed data points scattered around the line of regression [20] ) between the clinical assessment of disease activity and CDAI was not formally reported in the original report but was subsequently cited as 0.7 (21) . As a general rule of thumb, correlations of 0.5 to 0.75 indicate a moderate to good relationship and correlations in excess of 0.75 indicate a very good to excellent relationship (20) . The reliability of the CDAI by this rule of thumb, falls within the good to very good range.
The original CDAI was developed from 112 patients; the CDAI was later re-analyzed after it had been applied to 1058 patients from two studies (22) . This was a study of test-retest reliability and the investigators re-derived the regression coefficients (b [1] [2] [3] [4] [5] [6] [7] [8] of the original eight independent item variables). A multiplication factor was then used to arrive at a new weighting factor for the eight items. The recalculated CDAI was found to be very similar to the original because the correlation co-efficient determinations between the original CDAI and the recalculated derivative for the four patient groupings of "very well" to "very poor" (based on physician global assessment) ranged from 0.969 to 0.994 (22) . Because the rederived CDAI did not differ significantly from the original, the investigators did not recommend any changes to the CDAI.
Intra-class correlation is another test of an instrument's reliability. Unlike Pearson's correlation co-efficient, which is derived from regression analysis, the ICC is determined from an ANOVA between total variance and components of this variance (17, 23) . Mathematically, a significant difference between the ICC versus the correlation co-efficient is that the y intercept of the correlation coefficient may not be zero for the correlation co-efficient, whereas it is zero for the ICC (17) . Nevertheless, comparability between the two tests is reported to be good (17) . Over 20 years after the development of the CDAI, Irvine et al (24) , in a study of the Inflammatory Bowel Disease Questionnaire (IBDQ) (a quality of life questionnaire), examined the ICC of several CD indexes including the CDAI. The analysis was based on 305 patients enrolled in a clinical trial and compared baseline scores with follow-up scores. The ICC of the CDAI in this case was 0.66, which is similar to the correlation coefficient of 0.7 from the original CDAI data (5) .
Despite relatively good reliability of the CDAI in the hands of experienced investigators, considerable interobserver variation in scoring individual cases has been demonstrated prospectively (25) . When clinicians attending a conference were asked to calculate activity scores for several indexes, including the CDAI, based on individual case history presentation, significant differences in CDAI scores were obtained. Formal tests of reliability were not performed; however, wide ranges in CDAI scores of several hundred points were obtained. The range of CDAI scores became narrower on retesting after discussion with the study participants. This experience demonstrates that the reliability of the CDAI -like any diagnostic skill -is, first, operatordependent with a learning curve and, second, improves as users become more experienced.
VALIDITY OF THE CDAI
For a medical or health care instrument or test to be clinically useful, it must possess validity. Although the term validity is used frequently and the meaning appears to be obvious, it is not a single concept. Conceptually, validity can take several forms. Classically, these forms of validity are grouped into construct validity, content validity and criterion validity (26) . Construct validity: Construct validity refers to the creation of an instrument based on known or postulated features (ie, the theoretical constructs) of a disease or condition. The selection of the original items of the CDAI by the focus group of expert gastroenterologists based on accepted features of the disease can be considered an example of construct validity -the items represent accepted features of CD and, therefore, their inclusion is valid. Content validity: Content validity refers to the concept that the instrument accurately reflects the disease that it purports to measure. An example of content validity is the assumption that a candidate who passes the Royal College certification examinations in gastroenterology, in fact, has the breadth of knowledge expected of a competent gastroenterologist. The requirement of content validity for the CDAI appears to be satisfied by the ability of the instrument to be responsive to changes in clinical disease severity (5, 22) as reflected by the derivation of threshold CDAI scores that allow categorization of patients with quiescent or active disease. As mentioned in the preceding section on reliability, the correlation coefficient of this relationship between CDAI scores and clinical disease severity was 0.7 (21) . Although the correlation coefficient indicates the variability of the observed data points around the line of regression and is an indicator of reliability, it is also an indicator of validity. If the null hypothesis -that there was no relationship between CDAI scores and disease severity -was true, then the correlation coefficient value would be expected to be closer to zero than unity.
Since the CDAI has been used as an instrument of evaluation in clinical trials, and, more importantly, that the findings of those trials have been accepted by practicing gastroenterologists for over 25 years, indicate that the CDAI possesses content validity.
While the CDAI appears to possess content validity in many circumstances, there are aspects of CD in which the CDAI does not reflect the effects of the disease. For instance, the CDAI is not suitable for pediatric patients with CD. This is hardly surprising because the CDAI was developed by adult gastroenterologists, and the instrument, therefore, fails to possess construct validity for children whose disease manifestation/presentation may differ from that of adults. A pediatric CDAI has been developed (27) .
The domains of the CDAI also may not adequately cover all aspects of adult CD that are important to patients and their families. In terms of quality of life, including psychological, social, sexual and occupational functioning, the CDAI does not possess content validity. As Garrett and Drossman (28) point out, a patient with a low CDAI score may, in fact, be severely limited by the disease in these areas. In order to cover these qualitative aspects of CD in which the CDAI has poor content validity, quality of life instruments have been developed for IBD (these will be discussed later).
Criterion validity: Criterion validity refers to the ability of an instrument to correlate positively and significantly with an established or accepted gold standard test (26) . The heterogeneous manifestations of CD and the many possible diagnostic studies available -including endoscopic, radiologic, nuclear and laboratory studies -make choosing a gold standard test difficult. In fact, over the past 25 years, the CDAI itself become the gold standard instrument, with other diagnostic tests compared with it. Nonetheless, because the CDAI is based on mostly clinical features, including those self-reported by the patient, it would be of interest to assess the comparativeness of the CDAI with more objective diagnostic modalities that assess mucosal inflammation.
Studies comparing markers of mucosal inflammation with the CDAI generally have not demonstrated significant correlations and have sometimes yielded conflicting results. It is important to realize a priori that many of the studies have not involved large numbers of patients, that the diagnostic tests themselves are only surrogate markers of inflammation and that, in many cases, the CDAI was the gold standard of comparison. There has been only poor or weak correlation between the CDAI and direct endoscopic or microscopic mucosal examination in Crohn's colitis (29) (34) . The lack of a clearly positive correlation between mucosal inflammation and CDAI does not necessarily mean that the CDAI lacks criterion validity. Rather, this lack suggests that mucosal inflammation as detected by diagnostic testing is only one domain from which to assess CD severity.
Another aspect of criterion validity is the predictability of the instrument, ie, can the instrument predict a disease outcome? Wright et al (35) assessed several CD indexes as well as individual laboratory parameters, and noted that a rise in CDAI from baseline predicted an acute exacerbation of CD two months before the actual attack. Conversely, the CDAI in this study demonstrated a decrease towards baseline one month after the acute exacerbation, further suggesting that the CDAI possesses validity.
OTHER CD INDEXES POST-CDAI
Despite the intentions of the NCCDS to develop the CDAI with simplicity of application and computation in mind, the CDAI has been reported to be "cumbersome" (36) to use, and attempts have been made to simplify it. The most popular simplified derivative of the CDAI is the HarveyBradshaw Index (HBI) (37) , also known as the Simple Index and the Modified CDAI. Unlike the CDAI, which requires completion of a seven-day patient diary, the HBI looks only at symptoms and signs over the preceding 24 h. The HBI also reduced the original eight items of the CDAI to five, removing antidiarrheal use, hematocrit level and body weight, and eliminated the weighting factor. The HBI had a 93% corre-lation with the CDAI in the original prospective study of 112 patients (37) . This high correlation has been duplicated in later studies (29, 35) . The HBI clearly possesses easier practical application and is amenable to same-day clinic visits. The previous day nature of the HBI, however, introduces the possibility of less reliability versus the CDAI's seven-day patient diary. The ICC of the HBI in Irvine et al's study (24) was 0.55 (versus 0.66 for the CDAI).
It has been suggested that the frequency of diarrhea item introduces the strong possibility of single-parameter bias within the HBI (38) . In an effort to avoid this bias, the Cape Town Index (CTI) (also known as the South African Index) (38) was developed. Similar to the HBI, the CTI is also a derivative of the CDAI. Parameters from the domains of patient subjective symptoms, physician clinical findings and laboratory data (Table 3 ) are included. The CTI was studied on 86 patients who made 1068 visits (38) . The correlation coefficient of the CTI and CDAI was 0.761, and was 0.810 of the CTI and HBI (the correlation between the HBI and CDAI in this study was 0.745).
Sandler et al (21) have pointed out that a significant shortcoming of the CDAI, as well as the other clinical indexes of CD, is the unsuitability for population survey research. In an effort to derive a new instrument from the CDAI that was suitable for survey research, these investigators reanalyzed data from a previously published study (7) . Using multiple regression analysis with the physician global assessment as the dependent variable and transforming the new index into CDAI equivalents, they derived a threevariable index from the original CDAI (21) . Scoring for this new index was calculated from the formula:
(3 x number of stools) + (10 x abdominal pain) + (8 x well-being)
The correlation coefficient for this new index compared with the original CDAI was 0.866. When the dataset of the new index and CDAI were divided into quartiles (ie, one quartile spans the 25th to 75th percentile), there was agreement in 61% of cases and 97% agreement within one quartile. Although the three-variable derivation of the CDAI seems to be very amenable to survey research with possible further conversion of the three variables to Likert or visual analogue scales, this derivation of the CDAI has not been used to any great extent in clinical research. Such a threeparameter instrument may not be of great appeal to clinicians conducting clinical trials because disease assessment is restricted to only one domain: patient subjective symptoms. Such a single domain index would be perceived as lacking face validity.
A total of 39% of the CDAI is derived from the domain of the patient's symptoms (eg, general well-being and pain). Strong objections to the subjective nature of the CDAI were raised a few years after publication of the NCCDS, and attempts have been made to determine CD activity on objective grounds only. The use of laboratory-based indexes (36, 39, 40) as a replacement for, or an adjuvant to, a clinical instrument has been suggested. One instrument that eliminated subjective criteria is the Van Hees Index (VHI) (41) (also referred to as the Dutch Index). The derivation of the VHI, akin to that of the CDAI, employed a multiple regression analysis with a step-wise deletion using a physician global assessment as the dependent variable. The final items included in the index were: sex, two laboratory parameters (serum albumin and erythrocyte sedimentation rate) and seven clinical features obtained through physician history or Adapted from reference 41. *Weight (kg) x 10/height (cm) 2 ; No mass = 1, dubious = 2, diameter <6 cm = 3, diameter 6-12 cm = 4, diameter >12 cm = 5; Well-formed = 1, soft = 2, watery = 3 physical examination (a weight:height index [the Quetelet index], abdominal mass, temperature, stool consistency, previous intestinal resection and extraintestinal manifestations). In determining the VHI score for the individual patient, the VHI items are not multiplied by a weighting factor to obtain a final score; instead, the VHI score is obtained by directly inserting the item value into the multiple regression equation (Table 4 ). VHI scores less than 100 imply quiescent disease, less than 150 imply mild disease, less than 210 imply moderate disease and greater than 210 imply severe disease. The correlation coefficient of the VHI regression analysis was 0.95. Comparing the CDAI with the VHI, Van Hees et al (41) reported a correlation of only 0.57 -a marginal correlation that has been subsequently noted by others (35, 38) . Of interest, although Wright et al (35) found a poor correlation between the VHI and CDAI, both had predictive ability regarding CD exacerbations, although the CDAI reportedly demonstrated greater sensitivity. The poor correlation between CDAI and VHI may suggest that the VHI differs in reliability although it may also suggest that the two instruments do not measure the same features of CD.
QUALITY OF LIFE IN CD AND THE IBDQ
As discussed in the previous section, some clinical investigators who raised objections to the inclusion of subjective patient-reported symptoms in the CDAI attempted to create indexes without them. Regardless, there has been an increasing awareness of the importance of quality of life issues surrounding CD in the past 10 years. The content of previous instruments of CD activity have generally reflected a physician's perspective of disease activity. Quality of life studies, however, have suggested that functional status from the patient's viewpoint may be more indicative of health care utilization than the physicians' (42) , and that patients are less likely to volunteer information regarding psychosocial impairment (43). Drossman et al (42) used a generic healthrelated quality of life questionnaire, the Sickness Impact Profile -which examines 12 areas of daily living -and an IBD-specific instrument, the Rating Form of IBD Patient Concerns -which assesses patient concerns and worries -to assess a mixed UC/CD cohort of patients (43 UC, 54 CD). These investigators reported that IBD patients are more likely to indicate functional impairment in psychosocial aspects of health, such as emotional behaviour, sleep, rest and social interactions, than control patients without IBD. Moreover, the IBD patients in their study indicated that functional impairment resided more in the psychosocial domains than in the physical. CD patients also indicated greater impairment than UC patients.
In the assessment of quality of life in CD, however, not all instruments may be sensitive enough to detect changes in functional impairment and may not be appropriate. For instance, results from a time trade-off questionnaire, in which patients indicate the total number of life-years of poor health they would be willing to trade for a lesser number of life-years of good health, indicated that almost half of the IBD patient sample (n=93) were unwilling to trade-off (43) .
The assessment of quality of life in IBD has led to the development of a disease-specific instrument: the IBDQ (44, 45) . In contrast to the VHI (41) (which intentionally excludes patient-self reporting), the IDBQ does not include physician-derived physical findings or laboratory data. The IDBQ is an interviewer-administered questionnaire, although a revised, self-administered, mail-in version has also been developed (46) . Unlike the proposed modified threevariable survey version of the CDAI (23), the IBDQ has gained a degree of acceptance and has been used as an adjuvant outcome measure in several studies (8, 10, 11) . The IBDQ, in its final form, consists of 32 questions that cover four domains: bowel symptoms, systemic systems, emotional function and social function (44, 45) (Table 5 includes an example of questions from each domain). Each question response is in the form of a seven-point scale.
The selection of items in the IBDQ came from an open questionnaire of both gastroenterologists and patients with IBD (n=77) (45) . The administered open questionnaire was derived from a literature review of both existing diseasespecific and -nonspecific instruments. A group of patients with IBD then assessed the items, and the 32 most important items were included in the final survey. The involvement of patients in the creation of the instrument differs from the development of the previously described CD instruments, which were entirely clinician-focused. The IBDQ was formally evaluated on 63 patients on two occasions, one month apart. IBD activity was also assessed with the VHI (41) for CD and the St Mark's index (47) for UC. Test-retest reliability (referred to as reproducibility) in stable patients revealed a small but statistically significant difference (paired Student's t test) in two of the four domains: bowel (5.5% change from baseline) and systemic symptoms (12.1% change from baseline), a finding that suggests a lesser degree of reliability in these domains.
Responsiveness of the IBDQ was suggested by the consistency of domain scores with changes in patient self-assessed global ratings (significance of score differences from baseline The VHI, as previously discussed, makes no attempt to assess subjective patient symptoms; therefore, the emotional domain of the IBDQ was assessed against the emotional function dimension of the Rand questionnaire. A significant correlation of 0.76 was determined, suggesting criterion validity in this domain.
The IBDQ was subsequently assessed in later studies. Love et al (46) compared a modified IBDQ in a cohort of IBD patients (n=182) with a sex-and age-matched control group (n=48). Comparison of scores between IBD and controls in each domain revealed statistically significant differences suggesting content validity (ie, the instrument distinguished IBD patients from healthy patients). Irvine et al (24) reassessed the IBDQ in a larger group of patients (n=305) with CD only (previously studied groups included both CD and UC). Reliability testing revealed an ICC among the four domains ranging from 0.65 to 0.67. (As previously mentioned, the ICC for the CDAI in this study was 0.66.) Criterion validity testing of the IBDQ versus the CDAI revealed baseline correlation coefficients from -0.5 for emotional function, -0.53 for systemic function, -0.56 for social function and -0.71 for bowel function (r=-0.67 for overall IBDQ score). The negative correlation merely denotes that higher IBDQ scores reflect less functional impairment whereas higher CDAI scores reflect worse disease activity. The eight-week follow-up correlation was lower for all domains except systemic function, which was unchanged (r=-0.37 for social function, r=-0.40 for emotional function and r=-0.60 for bowel function). The better correlation with bowel function and decreased correlation with emotional and social function reflects the differing degree of overlap between the CDAI and the IBDQ domains, as opposed to lack of criterion validity. The correlation with the CDAI in this study differed markedly from that of the original study (45) , which compared the VHI and found lower coefficients of correlation. This finding suggests less overlap in IBDQ domains and the VHI compared with the IBDQ and the CDAI. As noted, the correlation between the CDAI and the VHI is modest (35, 38, 41) , so one may infer that these instruments also tap into different domains of CD activity.
CONCLUSIONS
Since 1972, when the CDAI was first used in clinical research in the NCCDS, the CDAI has become the gold standard with which other instruments of disease assessment and diagnostic tests are compared. The CDAI demonstrates acceptable reliability, although the range of variability in scoring can be considerable with a learning curve effect (25) . The CDAI appears to be a valid instrument of assessment although it is not appropriate for all patient subgroups with CD (eg, children) and does not cover all domains of the CD spectrum (eg, psychosocial). The correlation of the CDAI with diagnostic markers of mucosal inflammation is inconsistent, which may reflect the lack of correlation with these markers and the global effects of CD on patients. Since the introduction of the CDAI, derivations of the index have been developed to facilitate its clinical administration (eg, the HBI [37] or the CTI [38] ) or to make the index more objective (ie, the VHI [41] ). Quality of life, from a patient perspective, including social and emotional function, has been poorly assessed by these instruments. The IBDQ (24, 44, 45) possesses both reliability and validity in these domains and can be used in combination with a traditional CD activity index in clinical research.
